CQUEST

📢CCTG Members - we've extended the deadline! Submissions now closing, Monday 18 May 2026 at 9 AM AEST. Feel free to get in touch with our team if you'd like to discuss an idea for submission: cquest@uts.edu.au. Application & guidelines: bit.ly/3OMBkgO

Registrations are open for the TOGA 2026 ASM! Take advantage of discounted rates - early bird closed May 31 2026. 📅 Dates: July 15-17 📍 Location: Pullman Melbourne Albert Park Register now > buff.ly/0CgXhZ5

Are you coming to the #ANZUP26 ASM in #Adelaide this June? @ANZUPTrials have partnered with @Qantas to offer special flight discounts. Read more on our website: anzup.org.au/asm-registrati… @BizEventsAdl @AdelaideCC

📢CCTG Members - applications are now open! 💰 Up to $20,000 AUD ✅ for two cancer-related QoL activities 🗓️ 12-month period 🤝 CQUEST support & guidance For more info & to apply, scan the QR code or click here: bit.ly/3OMBkgO

Calling all researchers in the TOGA Community! Abstract submissions for the 2026 TOGA ASM are closing soon. If you’re part of the TOGA community, don’t miss the chance to contribute to this year’s exciting program of presentations and discussions. Submission Deadline:

📢 Don't forget to register! Join CQUEST for a deep dive into the Movember Pan Cancer Initiative’s core outcome set. We’re discussing the future of patient-reported outcomes (PROs) in Australian clinical trials. 🎟️Free for all CTG members! 👉 bit.ly/3OGkLTz

Congrats to Radiation Oncologist Dr Therese Kang from @AlfredHealth who will undertake new research on long-term outcomes from prostate cancer after receiving TROG's inaugural Secondary Data Analysis (SDA) Grant, supported by Commercial Collective. ap1.hubs.ly/y0K2Wx0

Prof Dickon Hayne on @VJOncology: #GDISCO (via @KevinKeane92 at #EAU26) - successful first in human phase 1 trial. Now progressing to #GDISCOTEQ at #SouthMetropolitanHealthService with national rollout planned @ANZUPtrials @uwanews bit.ly/4tdD3dB

Just around the corner! 👉 Register here: bit.ly/3OGkLTz

Are you a member of the community involved in the support and care of people with cancer? Nominations are now open for the 2026 #JeannieFerrisAward - recognising outstanding contributions in improving cancer outcomes. Visit bit.ly/414KbNP

Tarlatamab is changing the game in SCLC. See the trial data, understand the PBS landscape, and master the clinical use. Secure your place at our Small Cell Lung Cancer Masterclass now 👉 🚨 Limited spots available. 📅 Date: March 20 ⏰ Time: 10:00AM - 4:30PM

Only one week remains to volunteer on the ISOQOL Awards Subcommittee or a Travel Scholarship Selection Panel! Submit your application by 16 March to get involved and help shape recognition in the HRQL field. Learn more: buff.ly/p5DnQZt

It's just one week until we kick off one of the biggest events of the year in the Australian & NZ RO calendar -- our ASM in Melbourne. Register to join us for a fabulous program covering the latest research & technology, and the future of clinical trials. ap1.hubs.ly/y0D7DL0

🔬 STRIVE clinical trial now open in Aotearoa, New Zealand ANZGOG, in partnership with @CDNCancerTrials (CCTG), is pleased to announce the activation of the STRIVE clinical trial in Aotearoa, New Zealand 🇳🇿 STRIVE (ANZGOG2109/2021; CCTG VU.2) represents an important step forward in advancing evidence-based surgical management for women diagnosed with vulvar squamous cell carcinoma (VSCC). VSCC accounts for more than 90% of vulvar cancers and arises via two distinct biological pathways: • HPV-associated • HPV-independent, often linked to lichen sclerosus Emerging evidence suggests these subtypes behave differently, with implications for surgical management and recurrence risk. However, optimal treatment strategies have not been formally tested in a prospective trial. STRIVE is an international, prospective stratification study designed to refine surgical decision-making based on tumour biology, including HPV status and molecular markers such as p53 and dVIN. The trial aims to: • Improve risk stratification • Inform margin assessment • Reduce recurrence rates • Support personalised treatment pathways For HPV-associated tumours, the study will assess whether less extensive surgery can safely reduce complications and improve function without increasing recurrence risk. For HPV-independent tumours, STRIVE will evaluate whether tailored surgical approaches can reduce the likelihood of recurrence where high-risk biological features are present. The first Australasian site at Auckland City Hospital opened on 30 January 2026 and is actively recruiting, with Dr Lois Eva as Principal Investigator. The study is co-chaired in ANZ by Professor Paul Cohen and Dr Lois Eva. Given the relative rarity of vulvar cancer, international collaboration is essential. STRIVE brings together global expertise to generate the evidence needed to strengthen clinical guidelines and improve outcomes for women. 🔗 ClinicalTrials.gov: NCT06358469 More information: anzgog.org.au/strive-trial #ClinicalTrials #GynaecologicalCancer #VulvarCancer #CancerResearch #GlobalCollaboration

The consumer voice is vital for cancer clinical trials. Bring your lived experience to the table and help shape the future of consumer learning at our CQUEST Co‑Design Workshop. 👉For more info & to register: bit.ly/3MPXEoZ

CQUEST is bringing experts and insights together for this lunchtime seminar. Come along and learn about the core outcome set developed through the Movember Pan Cancer Initiative! 👉 Register here: bit.ly/3OGkLTz FREE for all CTG members!

ASM news incoming.... The theme for the 2026 TOGA ASM is Shaping Tomorrow’s Thoracic Cancer Care Together. We can't wait to see you there. 📅 Save the date: 15-17 July 2026 📍 Location: Pullman Melbourne Albert Park Find out more >buff.ly/4iRWqVO

Have questions about the financial impact of breast cancer? Join us for our free online Q&A on Wed, 18 March from 5-6:30 pm (AEDT) on the topic 'The Financial Impact of Breast Cancer', moderated by Author and Journalist, Annabel Crabb. Register here: bit.ly/49UheJc

Don't miss out on benefits! Renew your ISOQOL membership for 2026 by 31 January. Learn more at isoqol.org/membership/.

🚨 Don’t miss out on early bird savings! The Small Cell Lung Cancer Masterclass is an opportunity to deepen your understanding of this rapidly evolving disease and apply new evidence with confidence. ⏳ Early bird pricing closes 16 February 📅 Date: March 20